📊 ATRC Key Takeaways
Is AtriCure, Inc. (ATRC) a Good Investment?
AtriCure demonstrates strong revenue growth (+14.9% YoY) and excellent gross margins (75%), supported by robust free cash flow generation ($48.3M). However, persistent operating losses (-1.8% margin) and negative profitability despite substantial revenue raise concerns about the path to sustainable profitability and operational efficiency.
AtriCure shows strong fundamental improvement with nearly 15% revenue growth, very high 75.0% gross margins, and a sharp reduction in net losses, indicating progress toward sustainable profitability. The balance sheet is healthy, liquidity is strong, and positive operating cash flow plus free cash flow suggest the growth is supported by real cash generation rather than balance-sheet strain.
Why Buy AtriCure, Inc. Stock? ATRC Key Strengths
- Strong revenue growth at 14.9% YoY indicates market demand and commercial execution
- Exceptional gross margin of 75% demonstrates pricing power and operational leverage potential
- Solid free cash flow of $48.3M (9% FCF margin) shows the business generates cash despite net losses
- Strong balance sheet with low leverage (0.13x Debt/Equity) and substantial cash position ($167.4M)
- Excellent liquidity ratios (3.96x current, 2.99x quick) provide financial flexibility
- Improving net income losses (-2.1% net margin vs worse prior year) shows trajectory toward profitability
- Revenue growth remains solid at 14.9% YoY, showing continued demand and business expansion
- Gross margin of 75.0% is exceptionally strong and provides room for future operating leverage
- Strong financial health with $167.43M in cash, low debt/equity of 0.13x, and positive free cash flow of $48.28M
ATRC Stock Risks: AtriCure, Inc. Investment Risks
- Persistent operating losses (-$9.4M) despite $534.5M revenue scale raises questions about cost structure and operational efficiency
- Negative interest coverage (-5.6x) indicates inability to cover interest from operating earnings; dependent on FCF and cash reserves
- Net losses continue (-$11.4M) though improved, suggesting the company has not achieved sustainable profitability despite scale
- Heavy R&D and SG&A burden appears to be suppressing operating leverage despite strong gross margins
- Medical device sector competitive pressures and regulatory risks could impact future growth sustainability
- The company is still unprofitable at the operating and net income level, so execution risk remains
- Negative interest coverage reflects weak earnings relative to financing costs despite low leverage
- Growth quality must continue to translate into durable margin expansion, not just higher revenue
Key Metrics to Watch
- Operating margin progression toward breakeven and profitability
- Revenue growth sustainability and market penetration rates
- Operating cash flow relative to net income - sustainability of cash generation vs. accounting losses
- Gross margin maintenance as revenue scales
- Cash burn rate and runway given current operating structure
- Operating margin progression toward sustained positive profitability
- Free cash flow consistency alongside continued double-digit revenue growth
AtriCure, Inc. (ATRC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.96x current ratio provides a solid financial cushion.
ATRC Profit Margin, ROE & Profitability Analysis
ATRC vs Healthcare Sector: How AtriCure, Inc. Compares
How AtriCure, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AtriCure, Inc. Stock Overvalued? ATRC Valuation Analysis 2026
Based on fundamental analysis, AtriCure, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AtriCure, Inc. Balance Sheet: ATRC Debt, Cash & Liquidity
ATRC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: AtriCure, Inc.'s revenue has grown significantly by 95% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.66 indicates the company is currently unprofitable.
ATRC Revenue Growth, EPS Growth & YoY Performance
ATRC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $115.9M | -$267.0K | $-0.01 |
| Q2 2025 | $116.3M | -$6.2M | $-0.13 |
| Q1 2025 | $108.9M | -$6.7M | $-0.14 |
| Q3 2024 | $98.3M | -$7.9M | $-0.17 |
| Q2 2024 | $100.9M | -$5.1M | $-0.11 |
| Q1 2024 | $93.5M | -$6.5M | $-0.14 |
| Q3 2023 | $83.2M | -$9.1M | $-0.20 |
| Q2 2023 | $84.5M | -$5.1M | $-0.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AtriCure, Inc. Dividends, Buybacks & Capital Allocation
ATRC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AtriCure, Inc. (CIK: 0001323885)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATRC
What is the AI rating for ATRC?
AtriCure, Inc. (ATRC) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATRC's key strengths?
Claude: Strong revenue growth at 14.9% YoY indicates market demand and commercial execution. Exceptional gross margin of 75% demonstrates pricing power and operational leverage potential. ChatGPT: Revenue growth remains solid at 14.9% YoY, showing continued demand and business expansion. Gross margin of 75.0% is exceptionally strong and provides room for future operating leverage.
What are the risks of investing in ATRC?
Claude: Persistent operating losses (-$9.4M) despite $534.5M revenue scale raises questions about cost structure and operational efficiency. Negative interest coverage (-5.6x) indicates inability to cover interest from operating earnings; dependent on FCF and cash reserves. ChatGPT: The company is still unprofitable at the operating and net income level, so execution risk remains. Negative interest coverage reflects weak earnings relative to financing costs despite low leverage.
What is ATRC's revenue and growth?
AtriCure, Inc. reported revenue of $534.5M.
Does ATRC pay dividends?
AtriCure, Inc. does not currently pay dividends.
Where can I find ATRC SEC filings?
Official SEC filings for AtriCure, Inc. (CIK: 0001323885) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATRC's EPS?
AtriCure, Inc. has a diluted EPS of $-0.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ATRC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, AtriCure, Inc. has a BUY rating with 68% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ATRC stock overvalued or undervalued?
Valuation metrics for ATRC: ROE of -2.3% (sector avg: 15%), net margin of -2.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ATRC stock in 2026?
Our dual AI analysis gives AtriCure, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ATRC's free cash flow?
AtriCure, Inc.'s operating cash flow is $57.3M, with capital expenditures of $9.1M. FCF margin is 9.0%.
How does ATRC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2.1% (avg: 12%), ROE -2.3% (avg: 15%), current ratio 3.96 (avg: 2).